Gynecologic oncology Clinical Trials

Recruiting gynecologic oncology studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat gynecologic oncology. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting gynecologic oncology studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting gynecologic oncology trials

Within

Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC)

for Cervical Cancer Screening

Sponsor: Boston Medical Center

Sex: Female·Age: 21 - 65

Code: NCT07226037

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

11 sites incl. Arcadia

Sponsor: City of Hope Medical Center

Sex: Female·Age: 18+

Code: NCT07741968

Apply to this trial

SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

for Endometrial Cancer

Sponsor: Hospital Universitari de Bellvitge

Sex: Female·Age: 18+

Code: NCT07462663·Phase 4

My Self-Sampling for HPV Awareness, Results, and Empowerment

for Cervical Cancer

Sponsor: Daisy Le

Sex: All·Age: 30 - 65·Accepts healthy volunteers

Code: NCT07296159

Development Of An Endometrial Cancer Educational Tool

for Endometrial Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: Female·Age: 18+

Code: NCT07739745

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

for Advanced Cervical Carcinoma

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT05521997·Phase 2

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

for Ovarian Cancer

1 site in Charleston

Sponsor: Medical University of South Carolina

Sex: Female·Age: 18 - 80

Code: NCT07720180·Phase 2

A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

for Ovarian Cancer

Sponsor: LG Chem

Sex: All·Age: 18+

Code: NCT07752875·Phase 1, Phase 2

Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

for Ovarian Cancer

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07797283·Phase 3

Tucatinib Continuation Study

for HER2-positive Breast Cancer

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07768358·Phase 4

Breast and Cervical Cancer Stigma in Rwanda

for Breast Cancer

Sponsor: Dana-Farber Cancer Institute

Sex: Female·Age: 18+

Code: NCT07663006

Signatera Assessment in Early-Stage Endometrial Cancer

for Endometrial Cancer

12 sites incl. Birmingham

Sponsor: Natera, Inc.

Sex: Female·Age: 18+

Code: NCT07339384

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

for Gynecologic Cancer

1 site in Lexington

Sponsor: Denise Fabian

Sex: Female·Age: 18+

Code: NCT07631572

Apply to this trial

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

for Pancreas Cancer

1 site in Oklahoma City

Sponsor: University of Oklahoma

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07732686

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

for Endometrial Neoplasms

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT07578649·Phase 3

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

for Ovarian Cancer

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT07743164·Phase 3

OCRA Distress & Unmet Needs

for Gynecologic Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07591623

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

for Head and Neck Cancer

1 site in Lexington

Sponsor: Mark Bernard

Sex: All·Age: 18 - 99

Code: NCT07770100·Phase 2

A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)

for Fallopian Tube Cancer

Sponsor: Daiichi Sankyo

Sex: Female·Age: 18+

Code: NCT07791732·Phase 3

An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-OV28) in Assessing the Quality of Life of Patients With Ovarian Cancer - Phase III

for Ovarian Cancer

Sponsor: Helios University Hospital Wuppertal

Sex: Female·Age: 18+

Code: NCT07465133

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

for Ovarian Cancer

Sponsor: Epitopea Ltd

Sex: Female·Age: 18+

Code: NCT07665515·Phase 1

Apply to this trial

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

for Ovarian Cancer

Sponsor: Sun Yat-sen University

Sex: Female·Age: 18 - 75

Code: NCT07776171·Phase 2

Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer

for Cervical Cancer

Sponsor: Anhui Provincial Hospital

Sex: Female·Age: 18+

Code: NCT07782697

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

for Ovarian Cancer

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT07776691·Phase 3

TR115 in ARID1A-Mutated Advanced Solid Tumors

for Ovarian Clear Cell Carcinoma

Sponsor: Tarapeutics Science Inc.

Sex: All·Age: 18 - 70

Code: NCT07793318·Phase 2

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

for Ovarian Cancer

Sponsor: Phrontline Biopharma

Sex: All·Age: 18+

Code: NCT07778498·Phase 1, Phase 2

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

for Human Immunodeficiency Virus (HIV)

2 sites incl. Atlanta

Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All·Age: 25+·Accepts healthy volunteers

Code: NCT07520188

Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression

for Ovarian Cancer

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sex: Female·Age: 18 - 70

Code: NCT07168083

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

for Fallopian Tube Carcinoma

1 site in Seattle

Sponsor: University of Washington

Sex: Female·Age: 18+

Code: NCT07495124·Phase 2

Apply to this trial

Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer

for Ovarian Cancer

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: Female·Age: 70+

Code: NCT07716800

Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer

for Ovarian Cancer

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Sex: Female·Age: 18+

Code: NCT07779538·Phase 3

Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer

for Cervical Cancer

Sponsor: The University of Hong Kong-Shenzhen Hospital

Sex: Female·Age: 18+

Code: NCT07781475

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

for Bladder Cancer

3 sites incl. Boston

Sponsor: Lumina Pharmaceuticals Inc

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07781852·EARLY_Phase 1

89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer

for Epithelial Ovarian Cancer

Sponsor: Peking University Cancer Hospital & Institute

Sex: Female·Age: 18+

Code: NCT07790939·EARLY_Phase 1

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

for Endometrial Cancer

1 site in Chapel Hill

Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: Female·Age: 18+

Code: NCT07078838·Phase 2

PITCH - Impacting Hereditary Cancer Testing

for Ovarian Cancer

1 site in Lexington

Sponsor: Rachel Miller

Sex: Female·Age: 18+

Code: NCT07090109

Massage, Oncology, Pain, Anxiety, Feasibility

for Gynecologic Cancer

1 site in Lexington

Sponsor: Jill Cole

Sex: Female·Age: 18 - 85

Code: NCT07502157

Apply to this trial

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

for Ovarian Cancer

1 site in Pittsburgh

Sponsor: Kalinski, Pawel, MD, PhD

Sex: Female·Age: 18+

Code: NCT07634094·Phase 2

Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

for Ovarian Cancer

Sponsor: ARCAGY/ GINECO GROUP

Sex: Female·Age: 18+

Code: NCT07637851·Phase 1, Phase 2

Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

for Endometrial Cancer

1 site in Oklahoma City

Sponsor: University of Oklahoma

Sex: Female·Age: 18+

Code: NCT07737795·Phase 2

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

for Platinum-Sensitive Ovarian Cancer

2 sites incl. Danbury

Sponsor: Genmab

Sex: Female·Age: 18+

Code: NCT07564141·Phase 3

Apply to this trial

CYTALUX Dose Extension Study

for Cancer in the Lung

Sponsor: On Target Laboratories, LLC

Sex: All·Age: 18+

Code: NCT07469202·Phase 4

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

for Ovarian Cancer

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Sex: All·Age: 18+

Code: NCT07714668·Phase 2

Apply to this trial

Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

for Low Grade Ovarian Serous Adenocarcinoma

Sponsor: Verastem, Inc.

Sex: Female·Age: 18+

Code: NCT07747506·Phase 2

Exercise Oncology Clinic Pilot Feasibility Trial

for Breast Cancer

1 site in Iowa City

Sponsor: Jess S. Gorzelitz

Sex: All·Age: 18+

Code: NCT07765927

Apply to this trial

Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies

for Gynecologic Cancer

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: Female·Age: 18 - 99

Code: NCT07702721

Implementation of New Models of Ovarian Carcinoma Resistant to Therapy

for Ovarian Cancer

Sponsor: Mario Negri Institute for Pharmacological Research

Sex: Female·Age: 18+

Code: NCT07757711

Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention

for Ovarian Cancer

Sponsor: St. Joseph's Healthcare Hamilton

Sex: Female·Age: All ages

Code: NCT07761416·EARLY_Phase 1

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

for Epithelial Ovarian Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07545460·Phase 3

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

for Ovarian Cancer

Sponsor: West China Hospital

Sex: Female·Age: 18 - 75

Code: NCT07676890·Phase 1

DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays

for Ovarian Cancer

Sponsor: National and Kapodistrian University of Athens

Sex: Female·Age: 35+·Accepts healthy volunteers

Code: NCT07693894

Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers

for HIV (Human Immunodeficiency Virus)

Sponsor: Shenzhen Third People's Hospital

Sex: All·Age: 18+

Code: NCT07696169

Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

for Endometrial Neoplasms

Sponsor: Peking University People's Hospital

Sex: Female·Age: Up to 46

Code: NCT07714070·Phase 2

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

for Ovarian Cancer

Sponsor: West China Hospital

Sex: Female·Age: 18 - 75

Code: NCT07724106·Phase 1

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

for Ovarian Cancer

3 sites incl. Fort Lauderdale

Sponsor: University of Miami

Sex: Female·Age: 18+

Code: NCT06412120·Phase 4

Apply to this trial

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

for Melanoma (Skin Cancer)

Sponsor: Peking University Third Hospital

Sex: All·Age: 18 - 75

Code: NCT07760012

Apply to this trial

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

for PIK3CA Mutations

11 sites incl. Scottsdale

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07383506·Phase 1

Apply to this trial

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

for Ovarian Cancer

6 sites incl. Orlando

Sponsor: ArriVent BioPharma, Inc.

Sex: Female·Age: 18+

Code: NCT07755436·Phase 1

Apply to this trial

A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）

for Ovarian Cancer

Sponsor: NING LI-GYN

Sex: Female·Age: 18+

Code: NCT07690332

Evaluation of XYA02 in Patients With Advanced Solid Tumors

for MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors

Sponsor: XYone Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT07670312·Phase 1, Phase 2

New trials in Birmingham, AL?

Pick a condition and we'll email you once a week when a new study starts recruiting in Birmingham, AL. Unsubscribe anytime.

Gynecologic oncology clinical trials — common questions

Are gynecologic oncology clinical trials free to join?

Yes. Participating in a gynecologic oncology clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a gynecologic oncology clinical trial?

Each gynecologic oncology study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a gynecologic oncology trial near me?

Use the location controls above. We'll show recruiting gynecologic oncology trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many gynecologic oncology trials are recruiting right now?

We're currently tracking roughly 471 recruiting gynecologic oncology trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Gynecologic oncology trials by city

Birmingham, AL Boston, MA Los Angeles, CA Duarte, CA Chicago, IL San Francisco, CA Aurora, CO Little Rock, AR La Jolla, CA Orlando, FL Tampa, FL Denver, CO

Conditions in this area

Ovarian cancer Endometrial cancer Cervical cancer Uterine cancer Fallopian tube cancer Gynecologic cancer